108 related articles for article (PubMed ID: 36759733)
1. A reversible SRC-relayed COX2 inflammatory program drives resistance to BRAF and EGFR inhibition in BRAF
Ruiz-Saenz A; Atreya CE; Wang C; Pan B; Dreyer CA; Brunen D; Prahallad A; Muñoz DP; Ramms DJ; Burghi V; Spassov DS; Fewings E; Hwang YC; Cowdrey C; Moelders C; Schwarzer C; Wolf DM; Hann B; VandenBerg SR; Shokat K; Moasser MM; Bernards R; Gutkind JS; van 't Veer LJ; Coppé JP
Nat Cancer; 2023 Feb; 4(2):240-256. PubMed ID: 36759733
[TBL] [Abstract][Full Text] [Related]
2. Secondary resistance to anti-EGFR therapy by transcriptional reprogramming in patient-derived colorectal cancer models.
Vangala D; Ladigan S; Liffers ST; Noseir S; Maghnouj A; Götze TM; Verdoodt B; Klein-Scory S; Godfrey L; Zowada MK; Huerta M; Edelstein DL; de Villarreal JM; Marqués M; Kumbrink J; Jung A; Schiergens T; Werner J; Heinemann V; Stintzing S; Lindoerfer D; Mansmann U; Pohl M; Teschendorf C; Bernhardt C; Wolters H; Stern J; Usta S; Viebahn R; Admard J; Casadei N; Fröhling S; Ball CR; Siveke JT; Glimm H; Tannapfel A; Schmiegel W; Hahn SA
Genome Med; 2021 Jul; 13(1):116. PubMed ID: 34271981
[TBL] [Abstract][Full Text] [Related]
3. Aberrant expression of the COX2/PGE
Yoshitake R; Saeki K; Eto S; Shinada M; Nakano R; Sugiya H; Endo Y; Fujita N; Nishimura R; Nakagawa T
Sci Rep; 2020 May; 10(1):7826. PubMed ID: 32385388
[TBL] [Abstract][Full Text] [Related]
4. Activated MKK3/MYC crosstalk impairs dabrafenib response in BRAFV600E colorectal cancer leading to resistance.
Pranteda A; Piastra V; Serra M; Bernardini R; Lo Sardo F; Carpano S; Diodoro MG; Bartolazzi A; Milella M; Blandino G; Bossi G
Biomed Pharmacother; 2023 Nov; 167():115480. PubMed ID: 37713993
[TBL] [Abstract][Full Text] [Related]
5. HSPA8 Activates Wnt/β-Catenin Signaling to Facilitate BRAF V600E Colorectal Cancer Progression by CMA-Mediated CAV1 Degradation.
Li B; Ming H; Qin S; Zhou L; Huang Z; Jin P; Peng L; Luo M; Zhang T; Wang K; Liu R; Liou YC; Nice EC; Jiang J; Huang C
Adv Sci (Weinh); 2024 Jan; 11(3):e2306535. PubMed ID: 37973552
[TBL] [Abstract][Full Text] [Related]
6. Inhibiting BRAF/EGFR/MEK suppresses cancer stemness and drug resistance of primary colorectal cancer cells.
Lamichhane A; Luker GD; Agarwal S; Tavana H
Oncotarget; 2023 Oct; 14():879-889. PubMed ID: 37791907
[TBL] [Abstract][Full Text] [Related]
7. FAK loss reduces BRAF
Gao C; Ge H; Kuan SF; Cai C; Lu X; Esni F; Schoen R; Wang J; Chu E; Hu J
Res Sq; 2024 Jan; ():. PubMed ID: 36778401
[No Abstract] [Full Text] [Related]
8. Systemic Therapy in BRAF V600E-Mutant Metastatic Colorectal Cancer: Recent Advances and Future Strategies.
Morris VK
Curr Colorectal Cancer Rep; 2019 Apr; 15(2):53-60. PubMed ID: 31762713
[TBL] [Abstract][Full Text] [Related]
9. BRAF inhibitors in colorectal cancer: Toward a differentiation therapy?
Herr R; Brummer T
Mol Cell Oncol; 2015; 2(4):e1002709. PubMed ID: 27308494
[TBL] [Abstract][Full Text] [Related]
10. Mitogen-activated protein kinase activity drives cell trajectories in colorectal cancer.
Uhlitz F; Bischoff P; Peidli S; Sieber A; Trinks A; Lüthen M; Obermayer B; Blanc E; Ruchiy Y; Sell T; Mamlouk S; Arsie R; Wei TT; Klotz-Noack K; Schwarz RF; Sawitzki B; Kamphues C; Beule D; Landthaler M; Sers C; Horst D; Blüthgen N; Morkel M
EMBO Mol Med; 2021 Oct; 13(10):e14123. PubMed ID: 34409732
[TBL] [Abstract][Full Text] [Related]
11. BRAF
Piercey O; Tie J; Hollande F; Wong HL; Mariadason J; Desai J
Clin Colorectal Cancer; 2024 Apr; ():. PubMed ID: 38816264
[TBL] [Abstract][Full Text] [Related]
12. Editorial: Molecular targets for the treatment of metastatic colorectal cancer.
Passardi A; Gibbons D
Front Oncol; 2023; 13():1341594. PubMed ID: 38156115
[No Abstract] [Full Text] [Related]
13. Loss of the receptors ER, PR and HER2 promotes USP15-dependent stabilization of PARP1 in triple-negative breast cancer.
Sun X; Tang H; Chen Y; Chen Z; Hu Z; Cui Z; Tao Y; Yuan J; Fu Y; Zhuang Z; He Q; Li Q; Xu X; Wan X; Jiang Y; Mao Z
Nat Cancer; 2023 May; 4(5):716-733. PubMed ID: 37012401
[TBL] [Abstract][Full Text] [Related]
14. Disrupting the phase separation of KAT8-IRF1 diminishes PD-L1 expression and promotes antitumor immunity.
Wu Y; Zhou L; Zou Y; Zhang Y; Zhang M; Xu L; Zheng L; He W; Yu K; Li T; Zhang X; Chen Z; Zhang R; Zhou P; Zhang N; Zheng L; Kang T
Nat Cancer; 2023 Mar; 4(3):382-400. PubMed ID: 36894639
[TBL] [Abstract][Full Text] [Related]
15. EZH2 inhibition remodels the inflammatory senescence-associated secretory phenotype to potentiate pancreatic cancer immune surveillance.
Chibaya L; Murphy KC; DeMarco KD; Gopalan S; Liu H; Parikh CN; Lopez-Diaz Y; Faulkner M; Li J; Morris JP; Ho YJ; Chana SK; Simon J; Luan W; Kulick A; de Stanchina E; Simin K; Zhu LJ; Fazzio TG; Lowe SW; Ruscetti M
Nat Cancer; 2023 Jun; 4(6):872-892. PubMed ID: 37142692
[TBL] [Abstract][Full Text] [Related]
16. Survival comparison of first-line treatment regimens in patients with braf-mutated advanced colorectal cancer: a multicenter retrospective study.
Meng Q; Zhao J; Yu Y; Wang K; Ren J; Xu C; Wang Y; Wang G
BMC Cancer; 2023 Feb; 23(1):191. PubMed ID: 36849918
[TBL] [Abstract][Full Text] [Related]
17. Role played by MDSC in colitis-associated colorectal cancer and potential therapeutic strategies.
Wang K; Wang Y; Yin K
J Cancer Res Clin Oncol; 2024 May; 150(5):243. PubMed ID: 38717677
[TBL] [Abstract][Full Text] [Related]
18. Sulfadiazine Exerts Potential Anticancer Effect in HepG2 and MCF7 Cells by Inhibiting TNFα, IL1b, COX-1, COX-2, 5-LOX Gene Expression: Evidence from In Vitro and Computational Studies.
Gomaa M; Gad W; Hussein D; Pottoo FH; Tawfeeq N; Alturki M; Alfahad D; Alanazi R; Salama I; Aziz M; Zahra A; Hanafy A
Pharmaceuticals (Basel); 2024 Jan; 17(2):. PubMed ID: 38399404
[TBL] [Abstract][Full Text] [Related]
19. The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
Feichtenschlager V; Chen L; Zheng YJ; Ho W; Sanlorenzo M; Vujic I; Fewings E; Lee A; Chen C; Callanan C; Lin K; Qu T; Hohlova D; Vujic M; Hwang Y; Lai K; Chen S; Nguyen T; Muñoz DP; Kohwi Y; Posch C; Daud A; Rappersberger K; Kohwi-Shigematsu T; Coppé JP; Ortiz-Urda S
Mol Cancer; 2024 Feb; 23(1):40. PubMed ID: 38383439
[TBL] [Abstract][Full Text] [Related]
20. The therapeutically actionable long non-coding RNA '
Feichtenschlager V; Chen L; Zheng YJ; Ho W; Sanlorenzo M; Vujic I; Fewings E; Lee A; Chen C; Callanan C; Lin K; Qu T; Hohlova D; Vujic M; Hwang Y; Lai K; Chen S; Nguyen T; Muñoz DP; Kohwi Y; Posch C; Daud A; Rappersberger K; Kohwi-Shigematsu T; Coppé JP; Ortiz-Urda S
Res Sq; 2023 Dec; ():. PubMed ID: 38077055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
